WNTinib

Product Description

WNTinib is a multi-kinase inhibitor with selectivity for mutant β-catenin (CTNNB1) in hepatocellular carcinoma compared to wild type hepatocytes (IC₅₀ ranges are 0.36 μM-0.54 μM in primary organoids; 0.28 μM-1 μM in primary human HCC cell lines and 0.45 μM-2.3 μM in human cell lines ). Also inhibits VEGFR2, PDE6D and VEGFR1 (IC₅₀ values are 0.3 μM, 0.3 μM and 0.6 μM respectively). Downregulates WNT and phospho-EZH2, upregulates trimethylation of H3K27 and normalises expression of apoptotic genes.

Solubility

Preparing Stock Solutions for WNTinib

The following data is based on the product molecular weight 498.39

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.01 mL	10.03 mL	20.06 mL
5 mM	0.40 mL	2.01 mL	4.01 mL
10 mM	0.20 mL	1.00 mL	2.01 mL
50 mM	0.04 mL	0.20 mL	0.40 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Rialdi WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma. Nat.Cancer 2023 PMID: 37537299